HIV Orange
AIDS Vaccine Basics is comprised of our popular Primer series, textbook-like chapters of about 800 words each that aim to translate the complex world of AIDS vaccine science into simple but informative language. Here you will find deftly written explanations on how different AIDS vaccine strategies work, what cells comprise the different arms of the human immune system, and how to interpret the results of AIDS vaccine trials. The page contains a searchable key that allows readers to track down Primer topics dating back to 2003.

Understanding the Impact of PrEP on AIDS Vaccine Trials
Vax June 2012
How have recent data on the antiretroviral drug Truvada and its possible approval as an HIV prevention drug affected the design of AIDS vaccine trials?
Read More »

Understanding the Complexities of Adenoviral Vector Vaccines
Vax March 2012
What are the potential advantages and disadvantages of using vectors derived from the adenovirus—which causes the common cold—as vehicles for AIDS vaccine candidates?
Read More »

Understanding How Viral Vector-based AIDS Vaccine Candidates are Manufactured
Vax January 2012
What are some of the challenges in developing viral vector-based vaccine candidates and how are scientists trying to overcome these challenges?
Read More »

Understanding the Effects of Hormonal Contraception on HIV Transmission
VAX November 2011
What are the risks and benefits of using hormonal contraception in HIV prevention trials?
Read More »

Understanding the Rationale for Combination Prevention Trials
Vax September 2011
What are the potential benefits of and complications with studying multiple prevention strategies in combination?
Read More »

Understanding How Adjuvants Boost Immune Responses
Vax July 2011
What have researchers learned about the use of substances called adjuvants that can augment the response to vaccination?
Read More »

Understanding HIV's Envelope Protein
Vax March 2011
What are the challenges to understanding this protein’s structure and how would revealing its structure impact the design of possible HIV vaccine candidates?
Read More »

Understanding How Broadly Neutralizing Antibodies Evolve
Vax January 2011

Read More »

Understanding Adaptive Clinincal Trial Designs
VAX November 2010

Read More »

Understanding the Costs and Benefits of AIDS Vaccine Efficacy Trials
VAX September 2010
Why are late-stage trials so expensive and why is it important to invest in them?
Read More »

Understanding if Broadly Neutralizing Antibodies are the Answer
VAX May 2010

Read More »

Understanding Advances in the Search for Antibodies Against HIV
VAX March 2010
What are some of the recent developments that are helping researchers identify new targets for HIV vaccine design?
Read More »

Understanding Antibody Functions: Beyond Neutralization
VAX January 2010
What other antibody functions are being explored to explain the RV144 results?
Read More »

Understanding Vaccine Licensure
Vax December 2009
What factors do regulatory bodies consider before licensing a vaccine for public use?
Read More »

Understanding the Hunt for Immune Correlates of Protection from RV144
Vax November 2009
How can the recently conducted AIDS vaccine trial in Thailand help inform researchers about the types of immune responses that can provide protection against HIV?
Read More »

Understanding the Statistical Analysis of Clinical Trial Results
Vax October 2009
What are some of the statistical methods that are used to interpret clinical trial results?
Read More »

Understanding Challenge Viruses
Vax September 2009
How does the choice of challenge virus affect the outcome of vaccine studies in nonhuman primates?
Read More »

Understanding the Role of Social Science Research in Clinical Trials
Vax August 2009
What can researchers learn from studying communities in preparation for AIDS vaccine clinical trials?
Read More »

Understanding Inclusion/Exclusion Criteria
Vax July 2009
What are come of the eligibility requirements for volunteers to participate in AIDS vaccine clinical trials?
Read More »

Understanding How Data is Collected in Clinical Trials
Vax June 2009
What are the methods used to ensure that data from AIDS vaccine trials are of high quality?
Read More »